Stock Ticker

  • Loading stock data...

Novartis AG (NYSE:NVS) Reports First REACH3 Study Data Showing JakaviĀ®’s Improving Patients Outcomes In chronic GvHD

Novartis AG (NYSE:NVS) has announced its third phase REACH3 study results, which showed that JakaviĀ® significant failure-free survival improvements in patients with steroid-refractory chronic graft-versus-host disease (GvHD) relative to best available therapy (BAT). Novartis reports positive REACH3 results of Jakavi in chronic GvHD The company presented the REACH3 results at the Annual 62nd American Society […]